{"id":"hcp1105","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HCP1105 works by binding to the androgen receptor and recruiting it for proteasomal degradation, thereby eliminating both the protein and its transcriptional activity. This mechanism differs from traditional androgen receptor antagonists by completely removing the receptor rather than simply blocking its function, potentially overcoming resistance mechanisms. This approach is designed to provide enhanced efficacy in androgen receptor-driven cancers.","oneSentence":"HCP1105 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:53.194Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Castration-resistant prostate cancer (CRPC)"},{"name":"Metastatic castration-resistant prostate cancer (mCRPC)"}]},"trialDetails":[{"nctId":"NCT02941796","phase":"PHASE1","title":"Pharmacokinetics and Safety of HCP1105 and Co-administration of HGP0918, HGP0816 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2016-06","conditions":"Hyperlipidemias","enrollment":68},{"nctId":"NCT02551172","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD","status":"UNKNOWN","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2014-10","conditions":"Hyperlipidemias","enrollment":270}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HCP1105","genericName":"HCP1105","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HCP1105 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein. Used for Castration-resistant prostate cancer (CRPC), Metastatic castration-resistant prostate cancer (mCRPC).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}